
22 Sep, 2022 New Analysis from ILLUMINATE-C Phase 3 Study of Lumasiran Presented at IPNA
Results from a post-hoc analysis of patients on hemodialysis in the ongoing ILLUMINATE-C Phase 3 open-label study of lumasiran in patients with advanced primary hyperoxaluria type 1 (PH1) were presented at the International Pediatric Nephrology Association (IPNA) Congress (Sept. 7-11, 2022).